Transplantation & Cellular Therapy Meetings | Conferences

Interim Data Targeting CD117 Show Promising MRD Results and Safety in MDS/AML

April 27, 2022

JSP191 combined with fludarabine, and low-dose total body radiation demonstrated facilitation of full donor myeloid chimerism, clearing of minimal residual disease, and a well-tolerated safety profile in older patients with myelodysplastic syndrome/acute myeloid leukemia receiving non-myeloablative allogenic hematopoietic cell transplantation.

CAR T Cells Shown Effective Without Increased Risk of CRS or ICANS in CNS-Involved LBCL

April 25, 2022

Looking at 4 CAR T-cell agents for the treatment of large B-cell lymphoma, a systematic review and analysis showed that these therapies do not appear to increase the risk of cytokine release syndrome or immune effector cell–associated neurotoxicity syndrome.

Long-Term OS Data for Axi-Cel Hint Short-Term EFS is a Surrogate End Point for R/R LBCL

April 24, 2022

According to a long-term analysis of the ZUMA-1 study, the overall survival rate yielded by axicabtagene ciloleucel may support 1- and 2-year event-free survival as a surrogate end point in relapsed/refractory large B-cell lymphoma.